A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

The purpose of this research study is to determine if a new investigational diabetes drug is safe and effective in treating people who have Type II diabetes mellitus with very high HbA1c or FPG (fasting plasma glucose) levels. The HbA1c test, also called the hemoglobin A1c test or glycated hemoglobin test, is a measurement of the average amount of sugar in the blood over the last 2 to 3 months. FPG is a test that measures the amount of sugar in the blood after an 8 hour fast.

Official Title

Conditions

– Non-Insulin-Dependent Diabetes Mellitus

Study Type

Interventional

Study Design

Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Further Details

Study Start

Eligibility & Criteria

Ages Eligible for Study: 18 Years – 70 Years, Genders Eligible for Study: Both Criteria Inclusion Criteria:Laboratory result for HbA1c >11% or FPG >270mg/dL Clinical diagnosis of Type II diabetes Prior treatment with diet and/or exercise alone, or less than 15 days of prior treatment with an oral anti-diabetic medication or insulin.

Total Enrolment

Contact Details

[1] Australia Camperdown, 2050, Australia; Not yet recruiting Study Coordinator 011-612 9515 8888 St. Leonards, 2065, Australia; Not yet recruiting Study Coordinator 011-612 9926 8388 Miranda, 2228, Australia; Recruiting Study Coordinator 011-612 9531 8733 Wollongong, 2500, Australia; Not yet recruiting Study Coordinator 011-612 4225 1188 Caulfield, 3162, Australia; Not yet recruiting Study Coordinator 011-613 9258 5947 Kippa-Ring, 4021, Australia; Recruiting Study Coordinator 011-617 3889 5019 Woolloongabba, 4102, Australia; Not yet recruiting Study Coordinator 011-617 3240 5914 Ashford, 5035, Australia; Not yet recruiting Study Coordinator 011-618 8297 0009 Perth, 6000, Australia; Not yet recruiting Study Coordinator 011-618 9224 0248 Fremantle, 6959, Australia; Recruiting Study Coordinator 011-618 9431 3229